Magnesium modifies fentanyl-induced local antinociception and hyperalgesia.
Fentanyl-induced hyperalgesia and antinociception after systemic administration has been shown in previous clinical and experimental studies. However, there is very little evidence regarding the local possible effects of fentanyl. The purpose of this study was to assess whether local (intraplantar) fentanyl administration can produce antinociception and hyperalgesia. In addition, we examined the effects of magnesium, N-methyl-D-aspartate receptor antagonist, on possible changes produced by fentanyl. The paw withdrawal latencies to radiant heat stimuli were measured to assess the thermal nociceptive actions. Intraplantar administration of fentanyl caused time and dose-dependent increase in the paw withdrawal latencies (antinociception). Coinjection of magnesium with fentanyl markedly enhanced the antinociception. However, fentanyl also markedly decreased paw withdrawal latencies 24 h after intraplantar administration (hyperalgesia). In the presence of magnesium, hyperalgesia after fentanyl administration was not observed. Consequently, following the fentanyl administration, local hyperalgesia after antinociception is a negative effect in pain treatment. Magnesium may not only prevent the hyperalgesia but also enhance antinociceptive effect of fentanyl.
Mert
Tufan
T
Department of Biophysics, Faculty of Medicine, Cukurova University, 01330 Balcali, Adana, Turkey. tufanmert@yahoo.com
Gunes
Yasemin
Y
Ozcengiz
Dilek
D
Gunay
Ismail
I
D000701:Analgesics, Opioid / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D004347:Drug Interactions; D004357:Drug Synergism; D005260:Female; D005283:Fentanyl / Q000494:pharmacology* / Q000633:toxicity; D006358:Hot Temperature; D006930:Hyperalgesia / Q000139:chemically induced / Q000517:prevention & control; D008274:Magnesium / Q000494:pharmacology*; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors
D000701:Analgesics, Opioid; D016194:Receptors, N-Methyl-D-Aspartate; D008274:Magnesium; D005283:Fentanyl
J Pharmacol Exp Ther. 1998 Feb;284(2):678-86
9454814
Neuroreport. 2003 Jan 20;14(1):1-7
12544821
J Pharmacol Exp Ther. 2001 Dec;299(3):811-7
11714863
Anesthesiology. 2006 Mar;104(3):570-87
16508405
Curr Pharm Biotechnol. 2003 Aug;4(4):270-4
14529429
Can J Anaesth. 2006 Dec;53(12):1180-5
17142651
Pain Manag Nurs. 2007 Sep;8(3):113-21
17723928
Ann Neurol. 2003 Mar;53(3):366-75
12601704
Anesthesiology. 2002 Feb;96(2):381-91
11818772
Anesth Analg. 2002 May;94(5):1263-9, table of contents
11973202
Prog Neurobiol. 1999 Jan;57(1):1-164
9987804
Anesthesiology. 2002 Mar;96(3):627-32
11873038
J Neurosci. 2001 Jun 1;21(11):4074-80
11356895
Neuron. 2001 Jul 19;31(1):75-85
11498052
J Neurosci. 1995 Jan;15(1 Pt 1):165-72
7823127
Pain. 2002 Dec;100(3):213-217
12467992
Anesth Analg. 2003 Oct;97(4):1108-1116
14500166
Pharmacol Rev. 2003 Mar;55(1):1-20
12615951
Anesthesiology. 2000 Feb;92(2):465-72
10691234
Pain. 2000 Feb;84(2-3):175-9
10666522
Neurosci Lett. 2004 Apr 22;360(1-2):85-9
15082185
Neuron. 1991 Aug;7(2):319-26
1678615
Curr Opin Pharmacol. 2001 Feb;1(1):62-5
11712537
Eur J Pharmacol. 2007 Mar 8;558(1-3):68-72
17196585
Brain Res. 2000 Dec 29;887(2):436-9
11134637